Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Healthy Japanese Volunteers

• Body weight [ Designated as safety issue: No ]
• Vital signs (Blood pressure) [ Designated as safety issue: No ]
• Vital signs (Pulse rate) [ Designated as safety issue: No ]
• ECG (ElectroCardioGram) [ Designated as safety issue: No ]
• Adverse events [ Designated as safety issue: No ]

• Area under the plasma NNC 90-1170 curve [ Designated as safety issue: No ]
• Maximum plasma NNC 90-1170 concentration, Cmax [ Designated as safety issue: No ]
• Time to maximum plasma NNC 90-1170 concentration, tmax [ Designated as safety issue: No ]
• Terminal elimination half-life, t1/2 [ Designated as safety issue: No ]
• 24-hour glucose profile in serum [ Designated as safety issue: No ]
• 24-hour insulin profile in serum [ Designated as safety issue: No ]
• 24-hour glucagon profile in plasma [ Designated as safety issue: No ]

This trial is conducted in Japan. The aim of this trial is to assess the safety and tolerability of NNC 90-1170 (liraglutide) in healthy Japanese male subjects.

• Diabetes
• Diabetes Mellitus, Type 2

• Drug: NNC 90-1170
  Single dose administered subcutaneously at four different dose levels: 2.5, 5.0, 10.0 and 15.0 mcg/kg. Following completion of each dose group, an evaluation will be performed to allow progression to the next dose group
• Drug: placebo
  Single dose administered subcutaneously at four different dose levels: 2.5, 5.0, 10.0 and 15.0 mcg/kg. Following completion of each dose group, an evaluation will be performed to allow progression to the next dose group

• Experimental: NNC 90-1170
  Intervention: Drug: NNC 90-1170
• Placebo Comparator: Placebo
  Intervention: Drug: placebo

Inclusion Criteria:

• Body Mass Index (BMI) between 18 and 27 kg/m^2, inclusive

Exclusion Criteria:

• Clinically relevant abnormalities of physical examination, laboratory values, vital signs or ECG findings at the screening, as judged by the Investigator or Sub-Investigator
• Presence of acute or chronic illness sufficient to invalidate the subject's participation in the study or to make it unnecessarily hazardous, as judged by the Investigator
• Blood pressure in supine position at the screening, after resting for 5 min, outside the ranges 90-150 mmHg systolic or 40-90 mmHg diastolic
• Heart rate in supine position at the screening, after resting for 5 min, outside the range 40-100 beats/min
• Alcohol intake within 48 hours prior to the screening
• Hepatitis B surface antigen, Hepatitis C antibodies or HIV (human immunodeficiency virus) antibodies positive
• Clinically relevant abnormal history or physical findings at the screening, which could interfere with the objectives of the study or the safety of the subject's participation, as judged by the Investigator
• History of significant allergy or hypersensitivity
• Known or suspected allergy to trial product or related products
• History of drug or alcohol abuse
• Smoking 10 cigarettes or more, or the equivalent, per day and is unwilling to refrain from smoking during 3 days prior to dosing and during the confinement period